UnitedHealth Group reported a strong Q3, exceeding revenue and adjusted EPS expectations, and significantly raised its 2026 adjusted EPS guidance. Management also indicated that current analyst consensus for 2027 earnings is too conservative, suggesting higher growth. Despite the positive financial results and outlook, the stock wobbled, partly due to ongoing concerns about medical costs, particularly from the No Surprises Act and high commercial utilization.
UnitedHealth Group (UNH) announced a robust third quarter, surpassing analyst estimates for both revenue and adjusted EPS, which saw a 61% jump year-over-year. The company also formally raised its 2026 adjusted EPS guidance to at least $20.50, up from a previous range of $19.50-$20. Furthermore, management explicitly stated that the current analyst consensus for 2027 EPS is too conservative, implying a higher growth trajectory. This news is a significant positive catalyst for UNH, indicating strong operational performance and future earnings potential. However, the stock's initial 'wobble' suggests that concerns over persistent medical costs, particularly from the No Surprises Act and high commercial utilization, are still weighing on investor sentiment, creating a short-term tension between strong fundamentals and cost pressures. Long-term, the raised guidance and optimistic outlook present a compelling investment case, but traders should monitor cost trends closely.